242 related articles for article (PubMed ID: 27385209)
1. Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Zhang W; Lv Y; Xue Y; Wu C; Yao K; Zhang C; Jin Q; Huang R; Li J; Sun Y; Su X; Jiang T; Fan X
Oncotarget; 2016 Sep; 7(37):59098-59114. PubMed ID: 27385209
[TBL] [Abstract][Full Text] [Related]
2. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
4. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.
Abounader R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):235-45. PubMed ID: 19192961
[TBL] [Abstract][Full Text] [Related]
5. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
6. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas.
Kwak HJ; Kim YJ; Chun KR; Woo YM; Park SJ; Jeong JA; Jo SH; Kim TH; Min HS; Chae JS; Choi EJ; Kim G; Shin SH; Gwak HS; Kim SK; Hong EK; Lee GK; Choi KH; Kim JH; Yoo H; Park JB; Lee SH
Oncogene; 2011 May; 30(21):2433-42. PubMed ID: 21278789
[TBL] [Abstract][Full Text] [Related]
8. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
9. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
10. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.
Sun Y; Zhang W; Chen D; Lv Y; Zheng J; Lilljebjörn H; Ran L; Bao Z; Soneson C; Sjögren HO; Salford LG; Ji J; French PJ; Fioretos T; Jiang T; Fan X
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3538-43. PubMed ID: 24550449
[TBL] [Abstract][Full Text] [Related]
11. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D
Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293
[TBL] [Abstract][Full Text] [Related]
12. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
[TBL] [Abstract][Full Text] [Related]
13. Sprouty proteins, masterminds of receptor tyrosine kinase signaling.
Cabrita MA; Christofori G
Angiogenesis; 2008; 11(1):53-62. PubMed ID: 18219583
[TBL] [Abstract][Full Text] [Related]
14. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma.
Ivliev AE; 't Hoen PA; Sergeeva MG
Cancer Res; 2010 Dec; 70(24):10060-70. PubMed ID: 21159630
[TBL] [Abstract][Full Text] [Related]
15. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
[TBL] [Abstract][Full Text] [Related]
16. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
17. RACK1 affects glioma cell growth and differentiation through the CNTN2-mediated RTK/Ras/MAPK pathway.
Yan Y; Jiang Y
Int J Mol Med; 2016 Jan; 37(1):251-7. PubMed ID: 26718491
[TBL] [Abstract][Full Text] [Related]
18. Sprouty gain of function disrupts lens cellular processes and growth by restricting RTK signaling.
Shin EH; Zhao G; Wang Q; Lovicu FJ
Dev Biol; 2015 Oct; 406(2):129-46. PubMed ID: 26375880
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction molecules in gliomas of all grades.
Ermoian RP; Kaprealian T; Lamborn KR; Yang X; Jelluma N; Arvold ND; Zeidman R; Berger MS; Stokoe D; Haas-Kogan DA
J Neurooncol; 2009 Jan; 91(1):19-26. PubMed ID: 18759130
[TBL] [Abstract][Full Text] [Related]
20. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]